356 related articles for article (PubMed ID: 15050913)
41. Re: Scholten et al. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. J Pathol 2003; 201: 460-465.
Moreno-Bueno G; Hardisson D; Prat J; Matías-Guiu J; Palacios J
J Pathol; 2004 Apr; 202(4):511-2. PubMed ID: 15095279
[No Abstract] [Full Text] [Related]
42. Immunoexpression of E-cadherin and beta-catenin correlates to survival of patients with hepatocellular carcinomas.
Garcia S; Martini F; De Micco C; Andrac L; Hardwigsen J; Sappa P; Lavaut MN; Le Treut YP; Charpin C
Int J Oncol; 1998 Feb; 12(2):443-7. PubMed ID: 9458373
[TBL] [Abstract][Full Text] [Related]
43. [Hepatocellular carcinoma - diagnosis and treatment].
Greten TF; Manns MP
Dtsch Med Wochenschr; 2008 Sep; 133(38):1907-10. PubMed ID: 18785082
[No Abstract] [Full Text] [Related]
44. Role of cell adhesion signal molecules in hepatocellular carcinoma cell apoptosis.
Su JM; Wang LY; Liang YL; Zha XL
World J Gastroenterol; 2005 Aug; 11(30):4667-73. PubMed ID: 16094707
[TBL] [Abstract][Full Text] [Related]
45. Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of p53 AND beta-catenin.
An FQ; Matsuda M; Fujii H; Tang RF; Amemiya H; Dai YM; Matsumoto Y
Int J Cancer; 2001 Aug; 93(4):468-74. PubMed ID: 11477549
[TBL] [Abstract][Full Text] [Related]
46. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation.
Cervello M; Giannitrapani L; La Rosa M; Notarbartolo M; Labbozzetta M; Poma P; Montalto G; D'Alessandro N
Int J Mol Med; 2004 May; 13(5):741-8. PubMed ID: 15067380
[TBL] [Abstract][Full Text] [Related]
47. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas.
Ihara A; Koizumi H; Hashizume R; Uchikoshi T
Hepatology; 1996 Jun; 23(6):1441-7. PubMed ID: 8675162
[TBL] [Abstract][Full Text] [Related]
48. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.
Laurent-Puig P; Legoix P; Bluteau O; Belghiti J; Franco D; Binot F; Monges G; Thomas G; Bioulac-Sage P; Zucman-Rossi J
Gastroenterology; 2001 Jun; 120(7):1763-73. PubMed ID: 11375957
[TBL] [Abstract][Full Text] [Related]
49. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice.
Anna CH; Iida M; Sills RC; Devereux TR
Toxicol Appl Pharmacol; 2003 Jul; 190(2):135-45. PubMed ID: 12878043
[TBL] [Abstract][Full Text] [Related]
50. The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner.
Lara-Pezzi E; Roche S; Andrisani OM; Sánchez-Madrid F; López-Cabrera M
Oncogene; 2001 Jun; 20(26):3323-31. PubMed ID: 11423982
[TBL] [Abstract][Full Text] [Related]
51. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1.
Devereux TR; Stern MC; Flake GP; Yu MC; Zhang ZQ; London SJ; Taylor JA
Mol Carcinog; 2001 Jun; 31(2):68-73. PubMed ID: 11429783
[TBL] [Abstract][Full Text] [Related]
52. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
53. Analysis of the beta-catenin/T cell factor signaling pathway in 36 gastrointestinal and liver cancer cells.
Ikenoue T; Ijichi H; Kato N; Kanai F; Masaki T; Rengifo W; Okamoto M; Matsumura M; Kawabe T; Shiratori Y; Omata M
Jpn J Cancer Res; 2002 Nov; 93(11):1213-20. PubMed ID: 12460462
[TBL] [Abstract][Full Text] [Related]
54. Hepatocellular carcinoma (primary cancer of the liver).
Barbare JC; Boige V; Boudjema K; Lescesne R; Trinchet JC
Gastroenterol Clin Biol; 2006 Sep; 30 Spec No 2():2S57-2S61. PubMed ID: 17151564
[No Abstract] [Full Text] [Related]
55. Hepatocellular carcinoma: status in the era of liver transplantation.
Singhal A; Jabbour N
J Okla State Med Assoc; 2009 Dec; 102(12):355-61. PubMed ID: 20131731
[No Abstract] [Full Text] [Related]
56. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.
Nhieu JT; Renard CA; Wei Y; Cherqui D; Zafrani ES; Buendia MA
Am J Pathol; 1999 Sep; 155(3):703-10. PubMed ID: 10487827
[TBL] [Abstract][Full Text] [Related]
57. K-ras mutation and loss of heterozygosity at 17p with beta-catenin accumulation in intramucosal carcinoma of the ileostomy in familial adenomatous polyposis: a case report.
Hata K; Watanabe T; Kawamura YJ; Ishigami H; Kanazawa T; Tada T; Zhao B; Koketsu S; Nagawa H
Dig Dis Sci; 2003 Dec; 48(12):2310-4. PubMed ID: 14714618
[No Abstract] [Full Text] [Related]
58. Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention.
Shiratori Y; Yoshida H; Omata M
Expert Rev Anticancer Ther; 2001 Aug; 1(2):277-90. PubMed ID: 12113033
[TBL] [Abstract][Full Text] [Related]
59. Loss of beta-catenin expression is associated with disease progression in malignant melanoma.
Osborne JE
Br J Dermatol; 2002 Jun; 146(6):1104. PubMed ID: 12072090
[No Abstract] [Full Text] [Related]
60. Abnormal beta-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China.
Cui J; Zhou XD; Liu YK; Tang ZY; Zile MH
World J Gastroenterol; 2001 Aug; 7(4):542-6. PubMed ID: 11819825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
